-
FerGene Appoints David Meek Chief Executive Officer
inFerGene, a new gene therapy company launched by Ferring Pharmaceuticals and Blackstone Life Sciences in November, today announced the appointment of David Meek as President and Chief Executive Officer …
-
FerGene announces pivotal Phase 3 study of nadofaragene firadenovec
inFerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, announced today positive results from the pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec …
-
Ferring and Blackstone Life Sciences invest over $570 million USD in novel gene therapy for bladder cancer patients
inFerring and Blackstone Life Sciences invest over $570 million USD in novel…
-
Heat-stable carbetocin has been added to the WHO Essential Medicines List for the prevention of excessive bleeding after childbirth
inFerring Pharmaceuticalstoday welcomes the World Health Organization’s (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML)…
-
Ferring announces changes to Executive Committee
inFerring Pharmaceuticals announced today that Lars Peter Brunse is retiring from his role as Executive Vice President and Chief Production Officer. Armin Metzger, previously Senior Vice President, Head of Global Pharmaceutical R&D, has been appointed
-
Ferring collaboration with digital health innovators WOOM aims to help more people build families faster
inFerring Pharmaceuticals and WOOM today announced a collaboration, which aims to improve and shorten the fertility journeys of the one in six couples who have difficulty conceiving…
-
Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries
inFerring welcomes the recent update to the World Health Organization (WHO) recommendations relating to uterotonics for the prevention of postpartum haemorrhage (PPH), with specific…
-
Ferring, Rebiotix and Karolinska Institutet extend collaboration to research next generation of microbiome treatments
inFerring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology.
PRESS RELEASE 2019
PRESS RELEASE 2019